https://orcid.org/0000-0002-5458-1897
References
- Sarzi-Puttini P, Giorgi V, Marotto D, et al. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16(11):645–660. doi: 10.1038/s41584-020-00506-w
- Lawson K. Emerging pharmacological strategies for the treatment of fibromyalgia. World J Pharmacol. 2017;6(1):1–10. doi: 10.5497/wjp.v6.i1.1
- D’Amico R, Impellizzeri D, Cuzzocrea S, et al. Aliamides update: palmitoylethanolamide and its formulations on management of peripheral neuropathic pain. Int J Mol Sci. 2020;21(15):5330. doi: 10.3390/ijms21155330
- Del Giorno R, Skaper S, Paladini A, et al. Palmitoylethanolamide in fibromyalgia: results from prospective and retrospective observational studies. Pain Ther. 2015;4(2):169–178. doi: 10.1007/s40122-015-0038-6
- Schweiger V, Martini A, Bellamoli P, et al. Ultramicronized palmitoylethanolamide (um-PEA) as add-on treatment in fibromyalgia syndrome (FMS): retrospective observational study on 407 patients. CNS Neurol Disord Drug Targets. 2019;18(4):326–333. doi: 10.2174/1871527318666190227205359
- Roehrs T, Withrow D, Koshorek G, et al. Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo. J Clin Sleep Med. 2020;16(3):415–421. doi: 10.5664/jcsm.8220
- Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8(3):171–181. doi: 10.1038/nrn2092
- Goebel A, Andersson D, Barker C, et al. Research recommendations following the discovery of pain sensitizing IgG autoantibodies in fibromyalgia syndrome. Pain Med. 2022;23(6):1084–1094. doi: 10.1093/pm/pnab338
- A proof-of-concept study to evaluate the efficacy and safety of rozanolixizumab to treat adult study participants with severe fibromyalgia syndrome. 2023 Mar 10 cited 2023 Apr 5]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT05643794
- Murck H, Harte S, Larkin T, et al. NYX-2925, a novel N-methyl-D-aspartate receptor positive allosteric-modulator, showed antinociceptive activity in functional neuroimaging evaluations correlated with improved patient reported pain and fibromyalgia symptoms (P1-4.001). Neurol. 2022;98(18 Supplement):295.
- Evaluate the efficacy and safety of NYX-2925 in subjects with fibromyalgia. 2022 Sep 16 cited 2023 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03249103
- Castellanos JP, Woolley C, Bruno KA, et al. Chronic pain and psychedelics: a review and proposed mechanism of action. Reg Anesth Pain Med. 2020;45(7):486–494. doi: 10.1136/rapm-2020-101273
- Open-label study to assess the safety and efficacy of TRP-8802 with psychotherapy in adult participants with fibromyalgia. 2021 Nov 19 cited 2023 Apr 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT05128162